Advertisement

New Insight: The State of Retina Today, and Where We're Heading with Arshad Khanani, MD

Published on: 

In the inaugural episode of "New Insight with Veeral Sheth, MD," Dr. Sheth speaks with Arshad Khanani, MD on exciting developments from 2022, and a look at both the conference and treatment landscape unfolding in 2023.

Are you excited to learn what’s new in sight?

The field of ophthalmology undergoes an evolution in the care landscape seemingly every day, as groundbreaking innovations and practice-changing research reshape what it means to be a healthcare provider. As providers of timely and topline clinical news and insights, HCPLive® is always aiming to provide content that reflects the new agenda of healthcare.

For that reason, we are excited to officially launch our newest KOL-led podcast offering, New Insight with Veeral Sheth, MD.

The Director of Clinical Trials at University Retina in Chicago, Sheth is actively involved in clinical research in retina, having participated in national trials for disease spaces such as age-related macular degeneration (AMD) and diabetic retinopathy. His work has been featured at major medical meetings, in peer-reviewed publications, and in textbook chapters.

This podcast will thus serve as a platform for a key leader in the space to converse with the most important movers and shakers in ophthalmology and examine transformations in the field. It will also serve as a peek behind the curtain, as Sheth and our guests debate and analyze what it means to be an ophthalmologist in the 21st century.

In the inaugural episode of New Insight, Sheth is joined by Arshad Khanai, MD, the Director of Clinical Research at Sierra Eye Associates in Reno, Nevada. Khanani is a leader in the clinical research space, serving as principal investigator for several clinical trials and having work published in numerous ophthalmology journals.  Colleagues and friends for nearly 20 years, in this episode, Sheth and Khanani discuss their history together and provide insight into their background and education in retina.

They dive into their research and describe recent clinical trials that have led to landmark drug approvals in 2022, including faricimab for wet AMD and diabetic macular edema. They go on to discuss potential approvals to come and what else may come to fruition in 2023, including the approval of avacincaptad pegol for geographic atrophy. Sheth and Khanani also make particular mention of their excitement for upcoming medical meetings in 2023, including Clinical Trials at the Summit.

Importantly, they highlight the importance of mentorship in medicine and their role as mentors to fellows and younger colleagues within the space, as they provide guidance for the next generation of thought leaders.

Every episode of New Insight will be made available here on HCPLive, and listeners can also subscribe on Spotify, Apple Podcasts, and our Youtube channel.

We hope you enjoy the first episode of New Insight with Veeral Sheth, MD featuring Arshad Khanani, MD. Keep an eye out for more!


Advertisement
Advertisement